Vertex Pharmaceuticals | Sustainability Performance
Develops and markets pharmaceuticals for serious diseases, including cystic fibrosis and genetic disorders.
1989
United States
5,001 - 10,000 employees
Pharmaceuticals
$10B+ in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#192
Overallⓘ#40
in United Statesⓘ#6
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Leading
Critical
Intensity
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Industry Benchmark
48.1
B/M 111.2
Powered by illuminem and GIST Impact
Controversy level
- Vertex Pharmaceuticals Inc, US major biotech (Trikafta cystic fibrosis franchise), has faced multiple US class actions over alleged inadequate disclosure of Trikafta CF customer concentration risks and the contested 2024 USD 4.9 billion Alpine Immune Sciences acquisition integration challenges, plus periodic US FDA enforcement scrutiny on Vertex pain management vanzacaftor pipeline affecting US institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.